HDL and the inflammatory response induced by LDL-derived oxidized phospholipids

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 4, 2001, Pages 481-488

  Navab, Mohamad ^a   Berliner, Judith A ^a   Subbanagounder, Ganesamoorthy ^a   Hama, Susan ^a   Lusis, Aldons J ^a   Castellani, Lawrence W ^a   Reddy, Srinivasa ^a   Shih, Diana ^a   Shi, Weibin ^a   Watson, Andrew D ^a   Van Lenten, Brian J ^a   Vora, Deven ^a   Fogelman, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; HDL; LDL; Oxidized phospholipids

Indexed keywords

APOLIPOPROTEIN; ARACHIDONIC ACID; ENZYME; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOXYGENASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENIC DIET; ATHEROSCLEROSIS; GENETIC ENGINEERING; GENETIC PREDISPOSITION; HYPERLIPIDEMIA; IMMUNITY; INFLAMMATION; INFLUENZA VIRUS; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0035045169     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.21.4.481     Document Type: Short Survey

References (84)

1. Cross-regulatory roles of IL-12 and IL-10 in atherosclerosis
2. Atherosclerosis: Basic mechanisms, oxidation, inflammation, and genetics
3. The Yin and Yang of oxidation in the development of the fatty streak: A review based on the 1994 George Lyman Duff Memorial Lecture
4. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein
5. Protective effect of high density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidized low density lipoprotein
6. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo
7. Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein
8. 2 in atherosclerosis, 2: Potential involvement of biologically active oxidized phospholipids
9. Bioactive products of phospholipid oxidation: Isolation, identification, measurement and activities
10. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils
11. Determinants of bioactivity of oxidized phospholipids: Specific oxidized fatty acyl groups at the sn-2 position
12. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins
13. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: Evidence that oxidation-specific epitopes mediate macrophage recognition
14. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity
15. Minimally modified low density lipoprotein induces monocyte chemotactic protein (MCP-1) in human endothelial and smooth muscle cells
16. Modified low density lipoproteins induce endothelial cell expression of granulocyte and macrophage colony stimulating factors
17. The role of the GRO family of chemokines in monocyte adhesion to MM-LDL stimulated endothelium
18. Induction of P-selectin by oxidized lipoproteins: Separate effects on synthesis and surface expression
19. Oxidized phospholipids activate PPARα and induce endothelial synthesis of monocyte activators
20. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating β1 integrin
21. Induction of monocyte binding to endothelial cells by MM-LDL: Role of lipoxygenase metabolites
22. Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice
23. Genetic differences in endothelial cells may determine atherosclerosis susceptibility
24. Determinants of atherosclerosis susceptibility in the C3H and C57BL/6 mouse model: Evidence for involvement of endothelial cells but not blood cells or cholesterol metabolism
25. Genetic susceptibility to atherosclerosis
26. LDL is a lipid hydroperoxide-enriched circulating lipoprotein
27. Mechanism(s) of cell-mediated oxidation of low density lipoprotein
28. Role of oxidized low density lipoprotein in atherogenesis
29. The oxidation hypothesis of atherosclerosis
30. Antioxidants and atherosclerosis: A current assessment
31. Lipid hydroperoxide involvement in copper-dependent and independent oxidation of low density lipoproteins
32. Preparation of lipid hydroperoxide-free low-density lipoproteins
33. Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke
34. 2-)-stimulated oxidation of low-density lipoprotein
35. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids
36. Recruitment of cell phospholipids and cholesterol by apoA-II and apoA-I: Formation of nascent apolipoprotein specific HDL that differ in size, phospholipid composition and reactivity with LCAT
37. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport
38. Mechanism of high density lipoprotein-mediated efflux of cholesterol from cell plasma membranes
39. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1
40. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3
41. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apoE-deficient mice
42. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein
43. Apolipoprotein J is associated with paraoxonase in human plasma
44. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio
45. Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein
46. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase
47. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R
48. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities
49. Novel function of lecithin-cholesterol acyltransferase: Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation
50. Impaired function of lecithin: Cholesterol acyltransferase in atherosclerosis-susceptible White Carneau pigeons: Possible effects on metabolism of oxidized phospholipids
51. Role of lecithin-cholesterol acyltransferase in the metabolism of oxidized phospholipids in plasma: Studies with platelet-activating factor acetylhydrolase-deficient plasma
52. A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation
53. Metabolism of oxidized phosphatidylcholines formed in oxidized low density lipoprotein by lecithin-cholesterol acyltransferase
54. Physiologic concentrations of homocysteine inhibit the human plasma GSH peroxidase that reduces organic hydroperoxides
55. The platelet activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein
56. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
57. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis
58. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions
59. Immune recognition of OxLDL in atherosclerosis
60. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response
61. Infection and inflammation induce LDL oxidation in vivo
62. Oxidized lipoproteins and infectious agents: Are they in collusion to accelerate atherogenesis?
63. HDL loses its anti-inflammatory properties during acute influenza A infection
64. Oxidized phospholipids induce changes in hepatic paraoxonase and apoJ but not monocyte chemoattractant protein-1 via interleukin-6
65. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism
66. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model
67. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II
68. Overexpression of apolipoprotein A-II in transgenic mice converts high density lipoproteins to proinflammatory particles
69. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease
70. Paraoxonase and coronary heart disease
71. Serum paraoxonase after myocardial infarction
72. Perinatal development of human blood esterases
73. 2 as an independent predictor of coronary heart disease
74. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease
75. Inflammatory markers of coronary risk
76. Independent prognostic value of elevated C-reactive protein in unstable angina
77. Circulating markers of inflammation for vascular risk prediction: Are they ready for prime time?
78. Acute-phase proteins and other systemic responses to inflammation
79. Elevated C-reactive protein levels in overweight and obese adults
80. The pathogenesis of coronary artery disease and the acute coronary syndromes
81. Role of inflammation in coronary plaque disruption
82. Site of intimal rapture or erosion of coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
83. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques